BioPorto A/S (CPH:BIOPOR)

Market Cap	680.77M -5.8%
Revenue (ttm)	40.29M +11.2%
Net Income	-82.12M
EPS	-0.15
Shares Out	495.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	955,555
Open	1.320
Previous Close	1.320
Day's Range	1.320 - 1.375
52-Week Range	0.839 - 1.526
Beta	1.28
Analysts	n/a
Price Target	n/a
Earnings Date	May 21, 2026

About BioPorto

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnos...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1917
• Employees: 46
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: BIOPOR

Financial Performance

In 2025, BioPorto's revenue was 40.29 million, an increase of 11.16% compared to the previous year's 36.24 million. Losses were -82.12 million, 20.3% more than in 2024.